ACADIA Pharmaceuticals Inc. (ACAD) announced Thursday morning that the FDA has agreed that the data from the Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing of a New Drug Application for the treatment of Parkinson's disease psychosis. ACADIA will no longer conduct the Phase III -021 study that was planned as a confirmatory trial.
ACADIA Pharmaceuticals has gapped open sharply higher Thursday and is now up 3.47 at $11.44 on above average volume. The stock has jumped to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.